AB Corporate Bond ETF (NASDAQ:EYEG) Share Price Passes Below 50-Day Moving Average – Should You Sell?

AB Corporate Bond ETF (NASDAQ:EYEG) shares passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $35.51 and traded as low as $35.45. AB Corporate Bond ETF shares last traded at $35.52, with a volume of 107 shares changing hands.

AB Corporate Bond ETF Stock Down 0.0%

The company has a market capitalization of $28.42 million, a price-to-earnings ratio of -21.14 and a beta of 0.23. The business’s 50-day moving average is $35.51 and its 200-day moving average is $35.82. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.01.

AB Corporate Bond ETF Increases Dividend

The firm also recently announced a monthly dividend, which was paid on Tuesday, April 7th. Investors of record on Wednesday, April 1st were given a dividend of $0.1433 per share. This is a boost from AB Corporate Bond ETF’s previous monthly dividend of $0.14. This represents a c) dividend on an annualized basis and a yield of 4.8%. The ex-dividend date was Wednesday, April 1st. AB Corporate Bond ETF’s payout ratio is presently -104.17%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC acquired a new position in AB Corporate Bond ETF during the fourth quarter valued at $34,000. Jane Street Group LLC acquired a new position in AB Corporate Bond ETF during the second quarter valued at $232,000. Finally, Wealth Enhancement Advisory Services LLC lifted its position in AB Corporate Bond ETF by 6.2% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 119,017 shares of the specialty pharmaceutical company’s stock valued at $4,301,000 after purchasing an additional 6,988 shares during the period. 64.16% of the stock is currently owned by institutional investors and hedge funds.

AB Corporate Bond ETF Company Profile

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.